Natera
Logotype for Natera Inc

Natera (NTRA) investor relations material

Natera Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Natera Inc
Jefferies Global Healthcare Conference summary18 Nov, 2026

Quarterly performance and market opportunity

  • Record quarter for Signatera growth and strong organic gross margin performance; ASPs rose sequentially for Signatera. Revenue grew 42% YoY ex-true-ups, with FY 2026 guidance reset to above $3B.

  • Signatera’s estimated annual revenue opportunity is ~$20B, with roughly $1B reached to date; FIND-CRC could double the addressable market in the relative near term.

Leadership transition

  • After eight years as CEO and 16 years at the business, Steve is stepping away; Solomon Moshkevich, a long-tenured leader across Signatera and other operations, is succeeding him.

  • The transition was described as friendly, with Steve available for a warm handoff; leadership continuity supports readiness for 2027.

Revenue ambition and reimbursement

  • The $6B-plus 2029 revenue target starts from roughly $3B in 2026 and assumes continued execution, including modest growth in women’s health and transplant and continued Signatera patient growth.

  • Signatera ASP of $1,450 is a 2029 goal versus a current range of ~$1,290-$1,450; achieving it depends on execution and positive clinical-trial readouts.

  • Nine Signatera MolDX applications are in flight; broader Medicare and Medicare Advantage tumor coverage could add $200-$300 to ASP, with finalized MolDX responses typically taking 9-12 months.

  • Further reimbursement levers include Medicare Advantage compliance, commercial coverage in biomarker states, and potential NCCN guideline adoption in colorectal and breast cancer over the next three years.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Natera earnings date

Logotype for Natera Inc
Q4 202626 Feb, 2027
Natera
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Natera earnings date

Logotype for Natera Inc
Q4 202626 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Natera, Inc. develops and commercializes molecular testing services for reproductive health. It provides Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to analyze chromosomal anomalies or subchromosomal aberrations; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or subchromosomal aberrations; and Anora product platform, a single tube platform to detect cell-free DNA in maternal blood.